Table 2.
Efficacy and safety results.
| EmboTrap II | ARISE II19 | ESCAPE3 | SWIFT PRIME20 | REVASCAT5 | Trevo221 | |
|---|---|---|---|---|---|---|
| Reperfusion rate (2b/3) | 76% | 80.2% | 72.4% | 83% | 65.70% | 68% |
| sICH | 0% | 5.3% | 3.60% | 0% | 1.90% | 4.50% |
| 90-days mRS 0-2 | 55.17% | 67.3% | 51.60% | 60% | 43.70% | 40% |
mRS: modified Rankin Scale; sICH: symptomatic intracerebral hemorrhage; ARISE: Analysis of Revascularization in Ischemic Stroke With EmboTrap; mRS: modified Rankin Scale; ESCAPE: Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion with Emphasis on Minimizing CT to Recanalization Times; SWIFT PRIME: Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment; REVASCAT: Randomized Trial of Revascularization with Solitaire FR Device versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting within Eight Hours of Symptom Onset.